CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
United States123 participantsStarted 2018-08-20
Plain-language summary
Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, characterizing their relevant features, and measuring their outcome. The timing cannot be more opportune, with therapeutic targets already identified, exceptional collaboration among researchers and with the patient community, and several drugs ready to benefit from a track to clinical testing in the next five years.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18 years of age and older
✓. Diagnosed with a brain CA (single or multiple)
✓. Had a SH within the past year (with demonstrated new lesional bleeding or hemorrhagic growth on diagnostic studies AND attributable new symptoms)
✓. Subject is able to provide informed consent
Exclusion criteria
✕. Spinal CA as source of SH
✕. Prior brain irradiation
✕. Cases where verification of SH with clinical and imaging review cannot be accomplished
✕. Prior or planned treatment of the symptomatic lesion (after neurosurgical consultation)
✕. Contraindication for administration of contrast agent or otherwise unwilling or unable to undergo research MRI studies
✕. Pregnant or breastfeeding women
What they're measuring
1
Rate of Recurrent Symptomatic Hemorrhage During the Two Year Follow-up Period in Patients With CASH.